健康元(600380.SH):注射用阿立哌唑微球獲得註冊批準
格隆匯5月9日丨健康元(600380.SH)公佈,公司控股子公司麗珠醫藥集團股份有限公司(簡稱:麗珠集團)全資子公司珠海市麗珠微球科技有限公司(簡稱:麗珠微球)收到國家藥品監督管理局覈準簽發的《藥品註冊證書》(證書編號:2025S01188),注射用阿立哌唑微球獲批上市。
注射用阿立哌唑微球是麗珠微球自主開發的長效緩釋製劑,適應症爲成人精神分裂症。注射用阿立哌唑微球每月給藥一次,可提高用藥依從性,有助於降低復發和入院比率,減輕患者經濟負擔和社會負擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.